Alkermes, after arbitration win over J&J, jacks up revenue forecast by $425M

Alkermes has bumped up its revenue forecast for 2023 by $425 million after winning a final award in its arbitration battle with Johnson & Johnson over the licensing of its NanoCrystal technology.